News Channels

07 Mar 2018 MD Anderson and Berkeley Lights Launch Optera Therapeutics to Accelerate Development of Cell Therapies for Cancer
07 Mar 2018 EIP Pharma Publishes Positive Alzheimer's Disease Clinical Study Data with Neflamapimod
07 Mar 2018 Ultragenyx Announces Positive Topline Results and DMC Review from First Cohort of Phase 1/2 Clinical Study of DTX301, an Investigational Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
07 Mar 2018 Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology
07 Mar 2018 Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
07 Mar 2018 Merck KGaA, Darmstadt, Germany, Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis
07 Mar 2018 CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS
07 Mar 2018 Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease
07 Mar 2018 Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda® (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
07 Mar 2018 Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
07 Mar 2018 Eisai and Purdue Pharma announce positive topline results from key clinical studies of lemborexant including first-ever phase 3 head-to-head superiority comparison versus zolpidem ER in patients with sleep disorder
07 Mar 2018 Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials
07 Mar 2018 Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
07 Mar 2018 Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1
06 Mar 2018 Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina
06 Mar 2018 Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China
06 Mar 2018 Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine
06 Mar 2018 Benitec Biopharma Launches its Phase 2 Oncology Study in Australia
06 Mar 2018 Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery
06 Mar 2018 Lyric Completes Enrollment in Phase 2 PROMOTE Study of LP101 (Ulimorelin) in Enteral Feeding Intolerance

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing